Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies.

Annals of hematology - 1 Jul 2010

Bacher Ulrike, Haferlach Claudia, Schnittger Susanne, Kohlmann Alexander, Kern Wolfgang, Haferlach Torsten

Abstract excerpt

Despite recent progress in molecular research in myeloid malignancies, in subsets of patients with myelodysplastic syndrome (MDS) so far no underlying mutation was identified. In the myeloproliferative neoplasms (MPNs), the JAK2V617F alone cannot explain the phenotypic heterogeneity. In acute mye...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Chromosomes, Human, Pair 4
Share to Dioxygenases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA-Binding Proteins

Share to Leukemia, Myeloid, Acute

Share to Myelodysplastic Syndromes

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins c-cbl

Source

Identifiers

PMID: 20195608
DOI: 10.1007/s00277-010-0920-6

Genes

CBL
TET2
FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20195608-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies.PMID 20195608Read ↗

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.Semantic proximity Read ↗

Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.Semantic proximity Read ↗

Mutations in chronic myelomonocytic leukemia and their prognostic relevance.Semantic proximity Read ↗

Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AMLSemantic proximity Read ↗

Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms.Semantic proximity Read ↗

TET2 mutations in cytogenetically normal acute myeloid leukemia: clinical implications and evolutionary patterns.Semantic proximity Read ↗

TET2 mutation in acute myeloid leukemia: biology, clinical significance, and therapeutic insights.Semantic proximity Read ↗

TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.Semantic proximity Read ↗

Mutation in TET2 in myeloid cancers.Semantic proximity Read ↗

TET2 mutations in myelodysplasia and myeloid malignancies.Semantic proximity Read ↗

Analysis of core mutation and TET2/ASXL1 mutations DNA methylation profile in myelodysplastic syndrome.Semantic proximity Read ↗

Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.